Leicester Institute for Pharmaceutical Innovation, Leicester School of Pharmacy, De Montfort University, Leicester, UK.
Department of Materials Science and Engineering, Kroto Research Institute, North Campus, University of Sheffield, Broad Lane, Sheffield S3 7HQ, United Kingdom.
Int J Pharm. 2019 Apr 20;561:236-243. doi: 10.1016/j.ijpharm.2019.03.015. Epub 2019 Mar 8.
While vascular endothelial growth factor (VEGF) is an acknowledged potent pro-angiogenic agent there is a need to deliver it at an appropriate concentration for several days to achieve angiogenesis. The aim of this study was to produce microspheres of biodegradable polylactic-co-glycolic acid (PLGA) tailored to achieve sustained release of VEGF at an appropriate concentration over seven days, avoiding excessive unregulated release of VEGF that has been associated with the formation of leaky blood vessels. Several formulations were examined to produce microspheres loaded with both human serum albumin (HSA) and VEGF to achieve release of VEGF between 3 and 10 ng per ml for seven days to match the therapeutic window desired for angiogenesis. In vitro experiments showed an increase in endothelial cell proliferation in response to microspheres bearing VEGF. Similarly, when microspheres containing VEGF were added to the chorionic membrane of fertilised chicken eggs, there was an increase in the development of blood vessels over seven days in response, which was significant for microspheres bearing VEGF and HSA, but not VEGF alone. There was an increase in both blood vessel density and branching - both signs of proangiogenic activity. Further, there was clearly migration of cells to the VEGF loaded microspheres. In summary, we describe the development of an injectable delivery vehicle to achieve spatiotemporal release of physiologically relevant levels of VEGF for several days and demonstrate the angiogenic response to this. We propose that such a treatment vehicle would be suitable for the treatment of ischemic tissue or wounds.
虽然血管内皮生长因子 (VEGF) 是一种公认的强效促血管生成剂,但需要将其以适当的浓度持续输送数天才能实现血管生成。本研究的目的是制备可生物降解的聚乳酸-共-羟基乙酸 (PLGA) 微球,以在适当的浓度下实现 VEGF 的持续释放,持续 7 天,避免过度不受调节的 VEGF 释放,这与形成渗漏血管有关。研究了几种配方来制备负载人血清白蛋白 (HSA) 和 VEGF 的微球,以实现 3 至 10ng/ml 的 VEGF 释放持续 7 天,以匹配血管生成所需的治疗窗口。体外实验表明,载有 VEGF 的微球可增加内皮细胞的增殖。同样,当含有 VEGF 的微球添加到受精鸡卵的绒毛膜中时,在 7 天内会增加血管的发育,这对于载有 VEGF 和 HSA 的微球是显著的,但对于仅载有 VEGF 的微球则不显著。血管密度和分支都增加了 - 这都是促血管生成活性的标志。此外,细胞显然向负载 VEGF 的微球迁移。总之,我们描述了一种可注射递送载体的开发,以实现数天内生理相关水平的 VEGF 的时空释放,并证明了对这种释放的血管生成反应。我们提出,这种治疗载体将适合治疗缺血组织或伤口。